The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price had a very impressive month in November 2023, rising by around 13%. That was a much stronger return than the S&P/ASX 200 Index (ASX: XJO) which rose by 4.5%.

As we can see on the chart above, the CSL share price has bounced from its 2023 low, but it's still over 15% lower than its 2023 high.

What happened in November?

It was a slow news month for the company last month, it didn't announce anything noteworthy at all.

However, in the middle of October, it did release a 'capital markets day' presentation that did include a number of positives – it's up more than 9% since then.

CSL pointed out it's the global number one in plasma protein therapies (a $38 billion industry), it's the global number two in flu vaccines (a $7 billion industry) and it's the global number one in iron deficiency (a $5 billion industry).

The ASX healthcare share said it's positioned for annual double-digit earnings growth because it operates in high-growth markets where it has durable products driven by "continued innovation and embedded know-how".

It also pointed to "yield enhancement" across plasma and manufacturing platforms and it's investing in immunoglobulin and cell capacity.

In terms of research and development, it's investing for growth, with near-to-mid-term launches and there are "longer-term opportunities across platforms and therapeutic areas."

CSL also revealed that it's looking to use generative AI to potentially do a number of things including accelerate the time to trial, improve 'pharmacovigilance' reporting, improve the patient experience, improve tenders, optimise inventory management, improve the donor experience and improve "enterprise search".

CSL shares viewed as a cheaper opportunity

During the month of November, we saw a few different experts call CSL shares a buy, including brokers. As reported by my colleague James Mickleboro, Goldman Sachs is expecting CSL to achieve higher profit margins and this could deliver stronger shareholder returns.

But, with the CSL share price now higher than a few weeks ago, the forward price/earnings (P/E) ratio is now not as cheap as it was. According to the projection on Commsec, the CSL share price is now valued at 28 times FY24's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »